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AZD9773 in patients with severe sepsis and
septic shock
Peter E Morris1*, Brian Zeno2, Andrew C Bernard3, Xiangning Huang4, Shampa Das4, Timi Edeki5,
Steven G Simonson6 and Gordon R Bernard7
Abstract
Introduction: Tumor necrosis factor-alpha (TNF-a), an early mediator in the systemic inflammatory response to
infection, is a potential therapeutic target in sepsis. The primary objective of this study was to determine the safety
and tolerability of AZD9773, an ovine, polyclonal, anti-human TNF-a Fab preparation, in patients with severe sepsis.
Secondary outcomes related to pharmacokinetic (PK) and pharmacodynamic (PD) parameters.
Methods: In this double-blind, placebo-controlled, multicenter Phase IIa study, patients were sequentially enrolled
into five escalating-dose cohorts (single doses of 50 or 250 units/kg; multiple doses of 250 units/kg loading and 50
units/kg maintenance, 500 units/kg loading and 100 units/kg maintenance, or 750 units/kg loading and 250 units/
kg maintenance). In each cohort, patients were randomized 2:1 to receive AZD9773 or placebo.
Results: Seventy patients received AZD9773 (n = 47) or placebo (n = 23). Baseline characteristics were similar
across cohorts. Mean baseline APACHE score was 25.9. PK data demonstrated an approximately proportional
increase in concentration with increasing dose and a terminal half-life of 20 hours. For the multiple-dose cohorts,
serum TNF-a concentrations decreased to near-undetectable levels within two hours of commencing AZD9773
infusion. This suppression was maintained in most patients for the duration of treatment. AZD9773 was well
tolerated. Most adverse events were of mild-to-moderate intensity and considered by the reporting investigator as
unrelated to study treatment.
Conclusions: The safety, PK and PD data support the continued evaluation of AZD9773 in larger Phase IIb/III
studies.
Introduction
Sepsis remains a major cause of mortality, despite signif-
icant advances in antibiotic therapy and medical tech-
nology [1,2]. Current options for managing sepsis
include treatment of underlying infection, restoration of
tissue perfusion and oxygenation, and other organ-
supportive methods [3]. In addition to the symptomatic
management of sepsis, modulation of the host response
to the infection is a desired goal. Drotrecogin alfa (acti-
vated) recombinant human (rh) activated protein C
(Xigris®) was, until recently, the only immunomodula-
tory drug specifically approved for the treatment of
severe sepsis. However, the drug was withdrawn in
October 2011 following the results of the placebo-con-
trolled PROWESS-SHOCK study, where the primary
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endpoint of a statistically significant reduction in 28-day
all-cause mortality was not met.
Based on current understanding of the inflammatory
cascade, the release of cytokines into the circulation is
recognized as an early and essential part of sepsis
pathology. Experimental and clinical data have shown
that the pro-inflammatory cytokine tumor necrosis fac-
tor-a (TNF-a) is a principal initiator of this cascade
[4,5]. TNF-a is one of the first cytokines to be released
by macrophages in response to infection [6] and, once
in the circulation, it causes systemic inflammation
through stimulating the widespread release of down-
stream cytokines, such as interleukin-6 (IL-6) and IL-8
[7]. Given its role as an early mediator of the inflamma-
tory response, TNF-a is an appropriate target for the
treatment of sepsis.
A large number of immunomodulatory agents have
been studied in the clinical setting. However, trials with
a variety of intact antibodies, fragment antigen-binding
(Fab) dimers and soluble receptors against TNF have so
far shown only limited signals of efficacy in sepsis [8,9].
AZD9773 is a preparation of polyclonal Fab fragments
obtained from sheep immunized with rhTNF-a.
AZD9773 has a number of potential advantages over
previously tested agents designed to neutralize TNF-a
[9]. Being a polyclonal product, it binds to more than
one domain of TNF-a [10], and as a monomeric Fab
fragment rather than an intact antibody or Fab’2 dimer,
it is likely to exhibit improved tissue penetration [11,12].
These fragments have been shown to neutralize TNF in
the lung in severe sepsis patients [13]. Antibody frag-
ments may also have a shorter serum half-life than
intact antibodies, enabling more controlled time-limited
TNF suppression.
CytoFab, an earlier development formulation of
AZD9773 with similar polyclonal anti-TNF-a activity,
has shown the potential therapeutic benefit of polyclonal
Fab fragments. In a Phase II study in patients with
severe sepsis, CytoFab reduced plasma TNF-a and IL-6
levels and increased the number of ventilator- and
intensive care unit (ICU)-free days compared with pla-
cebo [13]. In addition, all-cause 28-day mortality rates
were higher in the placebo than the CytoFab group (37
vs 26%; P = 0.274). Since completion of this study, sig-
nificant manufacturing changes have been introduced to
ensure quality and to facilitate increased production for
more extensive study of the drug product. The key
modification relates to the chromatographic purification
of the ovine Fab fragments, where an affinity chromato-
graphy step has been replaced with sequential anion and
cation exchange steps. The resultant product
(AZD9773) contains a substantially higher concentration
of non-specific Fab fragments than CytoFab. In vitro
cell-based assays [14] and in vivo primate
pharmacodynamic studies [15] confirm that the
increased fraction of non-TNF-a-directed Fabs does not
negatively affect the potency of the drug product. The
only apparent pharmacological difference is that
AZD9773 has a lower biological activity (measured as
TNF-a neutralizing units) per mg protein [15]; there-
fore, in order to deliver an equivalent unit dose, the pro-
tein dose of AZD9773 is higher than that required for
CytoFab.
The objectives of the current study were to character-
ize the safety and tolerability of various single and mul-
tiple doses of AZD9773 in patients with severe sepsis,
and also to perform a preliminary assessment of the
pharmacokinetics (PK) and pharmacodynamics (PD) of
AZD9773.
Materials and methods
Study design
This was a first-in-man, multicenter, double-blind, dose-
escalation Phase IIa study (clinicaltrials.gov identifier:
NCT00615017) to assess single and multiple (a loading
dose followed by maintenance doses given every 12
hours for five days) intravenous infusions of AZD9773
versus placebo (2:1) in patients with severe sepsis. The
study comprised a treatment period (Day 1 for single-
dose cohorts, Days 1 to 6 for multiple-dose cohorts),
then a follow-up period to Day 28. The institutional
review board and an independent ethics committee at
each site approved the study protocol and informed
consent was obtained from each subject or their legal
representative. The study was conducted in accordance
with Good Clinical Practice guidelines and the Declara-
tion of Helsinki.
Patient population
Key inclusion criteria included: male or female patients
aged ≥ 18 years with severe sepsis; clinical evidence of
infection; systemic inflammatory response syndrome
(SIRS); cardiovascular and/or respiratory organ dysfunc-
tion (according to the study definitions - see Additional
files 1, 2, 3). Study drug had to be administered within
36 hours of the qualifying organ dysfunction, which
itself had to occur within 24 hours of the SIRS criterion.
Before receiving the first dose of study drug, each
patient was required to have received at least one dose
of parenteral antibiotics. Key exclusion criteria included:
human immunodeficiency virus infection with a last
known CD4 count ≤ 50/mm3; patient moribund, with
death considered imminent (within 24 hours of sepsis
recognition); patient not expected to survive 90 days
because of an underlying medical condition; organ or
bone marrow transplant within the previous 6 months;
immunosuppressant therapy or treatment with anti-TNF
antibodies within the previous 2 months; active
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tuberculosis or severe chronic respiratory disease. The
use of immunosuppressant drugs, high-dose steroids
and anti-TNF antibodies other than the study drug was
prohibited during the study, as was administration of
the study drug outside of the ICU. Drotrecogin alfa
(activated) use was allowed at the discretion of the
investigator.
Dosing
Patients were sequentially recruited into five cohorts and
then randomized to receive AZD9773 (Table 1) or pla-
cebo; AZD9773 was administered as an intravenous
infusion.
Prior to use, AZD9773 was reconstituted with saline.
Maximum dose infusion volumes were either 100 or
250 mL (cohorts 4 or 5 loading dose only). Patients with
a body weight > 100 kg received doses corresponding to
100 kg. Placebo (0.9% saline solution) was administered
as an intravenous infusion in an equivalent volume to
the active treatment; blinding was maintained using
masking bags sealed with tamper-evident tape.
Assessments
Pharmacokinetic and pharmacodynamic assessments
Blood and urine samples were collected daily for PK
assessments of both AZD9773-specific and total Fabs
(TNF-a-specific Fab and all other non-TNF-directed
Fabs present in AZD9773). AZD9773-specific and total
Fabs were quantitatively determined using a direct sand-
wich ELISA format (Quotient Bioresearch, Fordham,
Cambridgeshire, UK) with specific detection reagents to
the total ovine IgG Fab fragments or against the anti-
TNF-a binding moiety of the drug. Concentrations were
determined using AZD9773 standard curves. Blood sam-
ples for cohorts 1 and 2 were collected pre-infusion, at
the end of the infusion and at 0.5, 1, 2, 4, 8, 12, 24, 48
and 72 hours post-infusion, while those for cohorts 3 to
5 were collected pre-infusion for the loading dose and
maintenance doses 5, 7 and 9 (that is, the last one), and
at the end of the infusion and at 0.5, 1, 2, 4, 8 and 12
hours post-infusion for the loading dose and last main-
tenance dose. Urine samples for cohorts 1 and 2 were
collected pre-infusion and for 72 hours post-infusion,
while those for cohorts 3 to 5 were collected pre-infu-
sion and for 12 hours post-infusion for the loading and
last maintenance dose.
PD assessments included measurement of TNF-a and
IL-6 in serum using the ELISA-based Quantikine high-
sensitivity human TNF-a/TNFSF1A enzyme immunoas-
say (R&D Systems, Minneapolis, MN, USA). In this sys-
tem a monoclonal antibody is used to capture TNF-a
present in the patient sample; bound TNF-a is then
detected using an enzyme-linked polyclonal antibody
specific for TNF-a. Blood samples were drawn pre-infu-
sion, 2 and 3 hours after the initial infusion ended (for
TNF-a only), and 24, 48, 72, 96, 120, 144 and 168 hours
after start of infusion. The limit of quantification (LoQ)
was 1.3 pg/mL for TNF-a [16] and < 0.70 pg/mL for
IL-6 [17]. Procalcitonin serum concentration, as an
exploratory marker of infection, was assessed at baseline
and Days 1, 5 and 7, using the LUMItest PCT immuno-
luminometric assay (Brahms Diagnostic, Berlin, Ger-
many); normal procalcitonin levels are < 0.5 ng/mL [18].
All sample analyses were conducted by Covance Central
Laboratory Services, Geneva, Switzerland.
Safety
Safety was assessed based on the frequency and severity
of treatment-emergent adverse events (TEAEs; defined
as events not present at baseline or that worsened in
severity following the start of treatment), serious TEAEs,
assessment of laboratory parameters, electrocardiogram
(ECG) measurements, and all-cause 28-day mortality.
AEs were assessed regularly throughout the study, were
coded according to the Medical Dictionary for Regula-
tory Activities (MedDRA v12.0) and were assumed to be
treatment emergent unless there was clear evidence that
the event was present at the first dose of study drug.
Blood samples for the laboratory assessment of hematol-
ogy, clinical chemistry and urinalysis parameters were
collected daily during treatment, as well as after 14 and
28 days. ECG measurements were performed daily
before infusion, at the end of infusion and approxi-
mately 4, 6 and 12 hours post-infusion (also 24 hours
post-infusion for AZD9773 cohorts 1 and 2).
General sepsis outcomes
Sepsis outcomes were evaluated based on:
Table 1 AZD9773 dosing regimens
AZD9773
cohort 1
AZD9773 cohort 2 AZD9773 cohort 3 AZD9773 cohort 4 AZD9773 cohort 5
Loading dose
× 1
50 units/
kg
(over 90
minutes)
250 units/kg
(over 225 minutes for first
three patients, then 95
minutes for next nine
patients)
250 units/kg
(over 65 minutes for first
three patients, then 60
minutes for next nine
patients)
500 units/kg
(over 90 minutes for first
three patients, then 60
minutes for next nine
patients)
750 units/kg
(over 75 minutes for first
three patients, then 60
minutes for next nine
patients)
Maintenance
doses × 9
50 units/kg
(over 30 minutes once every
12 hours)
100 units/kg
(over 30 minutes once every
12 hours)
250 units/kg
(over 30 minutes once every
12 hours)
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■ Sequential Organ Failure Assessment (SOFA) score
[19]: comprised six individual component scores. Failure
of an organ system was recorded the first time any of
the criteria specified in the individual components of
the SOFA score were > 1 after the start of the study
drug up to Day 14. Organ failure-free days were days
when the organ system SOFA score was ≤ 1; these were
assessed up to Day 14.
■ Organ failure assessment: measured using SOFA
scores collected up to Day 14. Total organ failure reso-
lution was defined as resolution of all organ failures
(either those present at baseline or starting post-
baseline).
■ Ventilator use: the number of ventilator-free days
was measured and defined as the number of days after
starting unassisted breathing to Day 28, assuming a
patient survived for at least two consecutive calendar
days after starting unassisted breathing and remained
free of assisted breathing.
■ Treatment-emergent infections: the number of
patients with positive cultures occurring prior to, or
infections (reported as AEs) occurring after, first dose
was assessed.
■ Quality of background care was characterized and
evaluated, in part, by assessment of time to first dose of
antibiotics, adequacy of fluid resuscitation, tidal volume
in patients receiving mechanical ventilation, and the
proportion of patients receiving stress ulcer and deep
vein thrombosis prophylaxis.
Human anti-sheep antibody (HASA) IgG and bridging assay
Anti-AZD9773 antibodies were semi-quantitatively
determined in human serum by utilizing ELISA antibody
screening assays [20-22]. Ninety-six-well microtitre
plates were coated with AZD9773 and incubated with
the unknown sample or positive controls. The anti-
AZD9773 antibodies present in the sample, or positive
control anti-serum from rabbit immune serum added to
the wells, bound to AZD9773 immobilized on the
microtitre plate. Detection was via addition of biotiny-
lated AZD9773 and ExtrAvidin-HRP. A cut-point factor
was applied to each plate for data interpretation. Confir-
matory and titration assays were carried out using the
same format. Samples were taken at baseline, Day 7 and
Day 28.
Statistical analysis
The determination of sample size was based on practical
requirements rather than any formal statistical sample
size calculation. The number of patients was selected to
facilitate collection of sufficient safety and PK/PD data
to inform the design of future sepsis studies with
AZD9773, without unnecessarily exposing patients to
the drug. Descriptive statistics were applied to summar-
ize the continuous data, including number of
observations, mean, geometric mean, standard deviation
(SD), coefficient of variation (%CV), median, minimum
and maximum. Categorical data were summarized in
terms of frequency counts and percentages. A signifi-
cance level of P <0.05 was employed in exploratory
analyses.
The safety population comprised all patients who
started an infusion of the study drug. The PK popula-
tion was a subset of the safety population, excluding
patients who had dosing errors that could affect the PK
of AZD9773.
Data and safety monitoring board
A Safety Review Committee reviewed safety data at reg-
ular intervals during the study and assessed the planned
dose escalation schedule. Additionally, an Independent
Data Monitoring Committee (IDMC) met at planned
intervals to review study issues and unblinded safety
data. IDMC procedures were described in the IDMC
Charter and were agreed to by each committee member.
Results
Patient disposition
The study was conducted at 27 centers in the USA from
January 2008 until July 2009. Of 73 patients enrolled, 71
were randomized and 70 received treatment (n = 47,
AZD9773; n = 23, placebo). One patient in AZD9773
cohort 4 died before receiving the drug and was
excluded from the safety and PK analyses. Three other
patients were excluded from the PK analysis due to dos-
ing errors. Overall (and classifying patients who died as
completers), 63 patients (90.0%) completed the treat-
ment period and 60 (85.7%) completed the 28-day study
period (Figure 1).
Baseline demographics and disease characteristics
The baseline demographic and disease characteristics
were generally balanced across the treatment groups
and were typical of patients with severe sepsis and/or
septic shock (Table 2).
Twenty-six patients (55.3%) across AZD9773 cohorts
had a culture-positive infection prior to study entry,
compared to eight patients (34.8%) in the placebo
group. The most commonly reported sites of infection
at baseline were the lung and abdomen (Table 3). The
overall median time from qualifying organ failure to
start of treatment was 21.5 hours (range 3 to 32 hours).
Across the study, antibiotics were initiated a median of
4.2 hours before first qualifying organ failure.
Pharmacokinetics of AZD9773
Maximum serum concentrations of AZD9773 total Fabs
were achieved at the end of infusion (EOI); levels subse-
quently decreased in a multi-phasic manner. There was
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an initial rapid decline, with concentrations decreasing
by 80 to 90% within the 12 hours after EOI. Following
this initial decline, a terminal phase of approximately 18
to 20 hours was observed for both single-dose cohorts.
The volume of distribution and clearance was deter-
mined from the single-dose cohorts and remained com-
parable across doses (Table 4).
Comparison of AUC0-12 following both single doses
and loading doses from the multiple-dose cohorts indi-
cated that exposure increased with increasing dose. A
similar observation was made when comparing mainte-
nance dose AUC0-12 from the multiple-dose cohorts.
This increase in exposure was approximately dose pro-
portional (Table 4). Dose normalization of the loading
and maintenance doses indicated accumulation of
AZD9773 following twice-daily dosing for 10 doses, with
an accumulation ratio between 1.6 and 1.9. This accumu-
lation ratio was as expected for the terminal half-life (t1/
2) of this compound and demonstrates an absence of
time dependency in the PK of AZD9773. The Cmin data
confirmed that steady state was achieved by the fifth
maintenance dose and were also consistent with t1/2.
The areas under the curves (AUCs) for specific Fabs
ranged from 7.3% to 9.1% (overall mean 8.4%) of the
AUC for total Fabs. This is a good agreement with the
specific Fab content (8.4%) of the administered drug
product. The apparent volume of distribution and t1/2
were similar for total and specific Fabs in the two sin-
gle-dose cohorts.
There was no evidence of reduced exposure to
AZD9773 in patients who received dialysis (n = 9). The
overall proportion of dose excreted in urine across
AZD9773 cohorts was approximately 15% (Table 4).
Pharmacodynamics of AZD9773
TNF-a concentrations
Median baseline TNF-a serum concentrations were gen-
erally similar across cohorts (range 3.6 to 5.8 pg/mL),
except for AZD9773 cohort 2 (9.8 pg/mL). Any result
below the LoQ was assigned that concentration (that is,
1 
Patients enrolled (n=73) 
Randomized (n=71) 
Enrollment/eligibility criteria not met (n=1) 
Consent withdrawn (n=1) 
COHORT 1 
Randomized 
(n=8) 
• Treated (n=8) 
COHORT 2 
Randomized 
(n=9) 
• Treated (n=9) 
COHORT  3 
Randomized 
(n=12) 
• Treated (n=12) 
COHORT 4 
Randomized 
(n=11) 
• Treated (n=10) 
COHORT 5 
Randomized 
(n=8) 
• Treated (n=8) 
PLACEBO 
Randomized  
(n=23) 
• Treated (n=23) 
Completed 
treatment (n=8) 
Discontinued* 
• TEAE (n=0) 
• Other (n=0) 
 
Discontinued* 
• TEAE (n=1) 
• Other (n=0) 
Discontinued* 
• TEAE (n=2) 
• Other (n=1) 
Discontinued* 
• TEAE (n=0) 
• Other (n=1) 
Discontinued* 
• TEAE (n=0) 
• Other (n=0) 
Discontinued* 
• TEAE (n=1) 
• Other (n=1) 
Completed 
treatment (n=8) 
Completed 
treatment (n=9) 
Completed 
treatment (n=9) 
Completed 
treatment (n=8) 
Completed 
treatment (n=21) 
*NOTE: Excluding death; 2, 4, 5, 1, 1 and 6 patients in AZD9773 cohorts 1–5 and placebo cohort died, but these were considered to have completed 
Discontinued* 
• Consent 
withdrawn 
(n=1) 
• Loss to 
follow-up 
(n=0) 
• Other (n=0) 
 
Discontinued* 
• Consent 
withdrawn 
(n=0) 
• Loss to 
follow-up 
(n=0) 
• Other (n=0) 
Discontinued* 
• Consent 
withdrawn 
(n=0) 
• Loss to 
follow-up 
(n=0) 
• Other (n=0) 
Discontinued* 
• Consent 
withdrawn 
(n=0) 
• Loss to 
follow-up 
(n=0) 
• Other (n=1) 
Discontinued* 
• Consent 
withdrawn 
(n=0) 
• Loss to 
follow-up 
(n=0) 
• Other (n=0) 
Discontinued* 
• Consent 
withdrawn 
(n=0) 
• Loss to 
follow-up 
(n=1) 
• Other (n=0) 
Completed 
study (n=7) 
Completed 
study (n=8) 
Completed 
study (n=9) 
Completed 
study (n=8) 
Completed 
study (n=8) 
Completed 
study (n=20) 
Figure 1 Patient disposition.
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Table 2 Baseline demographic and disease characteristics (safety population)
AZD9773
cohort 1
(50 U/kg)
(n = 8)
AZD9773
cohort 2
(250 U/kg)
(n = 9)
AZD9773
cohort 3
(250/50 U/kg)
(n = 12)
AZD9773
cohort 4
(500/100 U/kg)
(n = 10)
AZD9773
cohort 5
(750/250 U/
kg)
(n = 8)
Placebo (n
= 23)
Total
(n = 70)
Mean age ± SD, years 53.0 ± 11.8 49.7 ± 15.0 55.1 ± 10.8 53.0 ± 17.9 63.5 ± 16.1 58.9 ± 17.4 56.1 ±
15.5
Male:female, n 6:2 5:4 5:7 3:7 2:6 11:12 32:38
Race, n (%)
Caucasian/white 7 (87.5) 8 (88.9) 11 (91.7) 9 (90.0) 7 (87.5) 20 (87.0) 62 (88.6)
Black/African American 1 (12.5) 1 (11.1) 1 (8.3) 0 1 (12.5) 2 (8.7) 6 (8.6)
Other 0 0 0 1 (10.0) 0 1 (4.3) 2 (2.9)
Shock, n (%)
Yes 5 (62.5) 6 (66.7) 9 (75.0) 9 (90.0) 7 (87.5) 20 (87.0) 56 (80.0)
No 3 (37.5) 3 (33.3) 3 (25.0) 1 (10.0) 1 (12.5) 3 (13.0) 14 (20.0)
On ventilator, n (%)*
Yes 7 (87.5) 8 (100.0) 9 (81.8) 8 (88.9) 8 (100.0) 20 (87.0) 60 (89.6)
No 1 (12.5) 0 2 (18.2) 1 (11.1) 0 3 (13.0) 7 (10.4)
Missing 0 1 1 1 0 0 3
Shock + ventilator, n (%)* 4 (50.0) 5 (55.6) 7 (58.3) 7 (70.0) 7 (87.5) 17 (73.9) 47 (67.1)
Organ failures, n (%)**
0 1 (12.5) 0 1 (8.3) 0 0 0 2 (2.9)
1 0 0 2 (16.7) 2 (20.0) 2 (25.0) 1 (4.3) 7 (10.0)
2 2 (25.0) 3 (33.3) 2 (16.7) 1 (10.0) 1 (12.5) 5 (21.7) 14 (20.0)
3 3 (37.5) 4 (44.4) 3 (25.0) 3 (30.0) 1 (12.5) 9 (39.1) 23 (32.9)
≥ 4 2 (25.0) 2 (22.2) 4 (33.3) 4 (40.0) 4 (50.0) 8 (34.8) 24 (34.3)
APACHE II score (n = 8) (n = 9) (n = 12) (n = 10) (n = 7) (n = 22) (n = 68)
Mean ± SD 28.4 ± 10.3 25.1 ± 7.8 26.3 ± 11.1 22.9 ± 9.0 25.1 ± 8.8 26.6 ± 8.0 25.9 ± 8.9
SOFA score (n = 7) (n = 8) (n = 7) (n = 8) (n = 6) (n = 20) (n = 56)
Mean ± SD 11.9 ± 4.3 10.9 ± 3.6 10.4 ± 3.4 11.5 ± 2.6 10.3 ± 3.6 10.7 ± 3.0 11.0 ± 3.2
TNF-a concentration, pg/mL (n = 8) (n = 8) (n = 9) (n = 9) (n = 8) (n = 23) (n = 65)
Median (range) 4.7
(1.3 to 48.8)
9.8
(2.7 to 54.3)
3.6
(1.3 to 14.2)
3.7
(1.3 to 8.2)
5.8
(1.3 to 18.3)
5.0
(1.6 to 61.7)
5.2
(1.3 to
61.7)
IL-6 concentration, pg/mL (n = 7) (n = 7) (n = 9) (n = 8) (n = 7) (n = 19) (n = 57)
Median (range) 465
(18 to
23,733)
189
(47 to
85,183)
215
(24 to 13,849)
1403
(135 to 16,168)
336
(194 to
94,207)
454
(28 to
153,600)
336
(18 to
153,600)
Procalcitonin level, ng/mL (n = 8) (n = 8) (n = 10) (n = 10) (n = 6) (n = 23) (n = 65)
Median (range) 28.5 (1.8 to
456.4)
4.8
(0.3 to 250.9)
4.0
(0.3 to 800.3)
16.5
(1.3 to 89.6)
15.1
(2.5 to 17.1)
14.7
(0.3 to
328.5)
14.2
(0.3 to
800.3)
> 0.5 ng/mL, n (%) 8 (100) 7 (87.5) 7 (70.0) 10 (100) 6 (100) 22 (95.7) 60 (92.3)
Total fluid volume in 24 h prior to
randomization, mL/kg
(n = 8) (n = 9) (n = 11) (n = 7) (n = 8) (n = 23) (n = 66)
Median (range) 51.7
(23.8 to
167.6)
58.0
(6.4 to 158.6)
40.1
(11.1 to 183.4)
34.0
(17.2 to 196.8)
58.5
(29.3 to
434.1)
58.4
(8.7 to
373.5)
56.4
(6.4 to
434.1)
Relevant medical history, n (%)†
Diabetes 1 (12.5) 4 (44.4) 4 (33.3) 3 (30.0) 3 (37.5) 7 (30.4) 22 (31.4)
COPD 3 (37.5) 2 (22.2) 2 (16.7) 2 (20.0) 3 (37.5) 4 (17.4) 16 (22.9)
Chronic renal failure 1 (12.5) 2 (22.2) 0 1 (10.0) 0 0 4 (5.7)
Colon cancer 0 0 0 0 1 (12.5) 1 (4.3) 2 (2.9)
*Percentages exclude patients with a missing assessment; **Number of organ failures (SOFA score components > 1); †Reported in > 1 patient overall; COPD,
chronic obstructive pulmonary disease. Note: One patient in AZD9773 cohort 1 was recorded as having no organ failure as study drug was administered outside
the protocol-defined time limit. However, this resulted from a data entry error that was not amended in the clinical database; the patient did in fact receive
study drug within the defined time limit. One patient in AZD9773 cohort 3 was recorded as having no organ failure as they received study drug outside the
protocol-defined time limit; inclusion of this patient was a protocol deviation
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1.3 pg/mL). There was no discernible effect on total
TNF-a concentrations in AZD9773 cohort 1, while in
cohort 2, TNF-a concentrations decreased close to the
LoQ within two hours (Figure 2A). In AZD9773 cohorts
3 to 5, significant TNF-a reductions observed within
two hours post-infusion were maintained throughout
treatment (Figure 2B). In concordance with AZD9773
exposure, TNF-a inhibition decreased when dosing was
stopped (Figure 2B). In an exploratory analysis of TNF-
a AUC over treatment, significant reductions in TNF-a
concentrations were observed with maintenance
AZD9773 treatment across all three multiple-dose
cohorts compared with placebo (Figure 3).
IL-6 concentrations
Median IL-6 serum concentrations decreased in all
AZD9773 cohorts (from baseline to 48 hours: 465 to 99
pg/mL in cohort 1; 189 to 85 pg/mL in cohort 2; 215 to
163 pg/mL in cohort 3; 1403 to 165 pg/mL in cohort 4;
and 336 to 90 pg/mL in cohort 5). In the placebo group,
the median decreased from 454 to 68 pg/mL. There
were no obvious differences between individual
AZD9773 cohorts and placebo.
Procalcitonin levels
Median baseline procalcitonin levels were 28.5, 4.8, 4.0,
16.5 and 15.1 ng/mL in AZD9773 cohorts 1 to 5,
respectively, and 14.7 ng/mL in the placebo patients.
Procalcitonin values at baseline were above the reference
range (that is, > 0.5 ng/mL) in 60/65 patients (92.3%;
Table 2). On Day 7, procalcitonin levels had decreased
to 3.4, 0.4, 2.3, 0.6 and 1.5 ng/mL in AZD9773 cohorts
and to 0.5 ng/mL in placebo patients.
Safety of AZD9773
Adverse events
Most patients experienced at least one TEAE; the most
common TEAEs overall were anemia, agitation and
Table 3 Sites of clinically suspected infections and use of antibiotics at baseline (safety population)
AZD9773
cohort 1
(50 U/kg)
(n = 8)
AZD9773
cohort 2
(250 U/kg)
(n = 9)
AZD9773 cohort 3
(250/50 U/kg) (n
= 12)
AZD9773 cohort 4
(500/100 U/kg) (n
= 10)
AZD9773
cohort 5
(750/250 U/kg)
(n = 8)
Placebo (n =
23)
Total
(n = 70)
Infection site, n (%)
Abdomen 2 (25.0) 3 (33.3) 2 (16.7) 1 (10.0) 5 (62.5) 3 (13.0) 16 (22.9)
Catheter/device 1 (12.5) 0 0 0 0 0 1 (1.4)
Lung 3 (37.5) 4 (44.4) 6 (50.0) 6 (60.0) 2 (25.0) 12 (52.2) 33 (47.1)
Skin and soft
tissue
1 (12.5) 1 (11.1) 1 (8.3) 1 (10.0) 0 4 (17.4) 8 (11.4)
Unknown 1 (12.5) 1 (11.1) 2 (16.7) 2 (20.0) 0 1 (4.3) 7 (10.0)
Urinary tract 0 0 3 (25.0) 0 1 (12.5) 3 (13.0) 7 (10.0)
Time from qualifying organ failure to first antibiotic use, hours*
(n = 7) (n = 6) (n = 9) (n = 7) (n = 8) (n = 19) (n = 56)
Median
(range)
-4.4
(-39.0 to 20.6)
-10.1
(-85.7 to 0.7)
-0.8
(-41.3 to 16.4)
-3.9
(-108.2 to 1.2)
-6.3
(-85.1 to 6.5)
-4.9
(-366.5 to
12.8)
-4.2
(-366.5 to
20.6)
*A negative time indicates that antibiotics were given before qualifying organ failure
Table 4 Single- and multiple-dose PK of AZD9773 total Fabs
AZD9773 cohort 1
(50 U/kg)
(n = 7)
AZD9773 cohort 2
(250 U/kg) (n = 8)
AZD9773 cohort 3
(250/50 U/kg) (n = 6)§
AZD9773 cohort 4
(500/100 U/kg) (n = 7)§
AZD9773 cohort 5
(750/250 U/kg)
(n = 4)§
AUC0-12, μg.h/mL*
‡ 125.2 ± 79.8 581.0 ± 94.04 449.2 ± 46.8 691.5 ± 22.7 1872 ± 28.4
AUC0-12, μg.h/mL* - - 162.8 ± 82.2 251.6 ± 56.0 981.0 ± 39.3
Cinf, μg/mL*
‡ 29.6 ± 112.5 156.2 ± 208.1 - - -
Cinf, μg/mL* - - 28.4 ± 52.9 42.5 ± 83.5 151.8 ± 14.7
Accumulation ratio* - - 1.9 ± 32.0 1.6 ± 79.1 1.6 ± 38.1
tmax, hours** 1.5 (1.4 to 3.5) 2.1 (1.0 to 4.3) 0.5 (0 to 0.7) 1.0 (0.4 to 8.5) 0.7 (0.5 to 1.6)
t1/2, hours
† 18.0 ± 7.3 19.8 ± 5.2 - - -
CL, mL/min/kg† 6.1 ± 3.4 7.6 ± 6.0 - - -
Vss, mL/kg
† 92.6 ± 30.8 152.8 ± 132.8 - - -
Dose excreted, %* 10.6 ± 69.3 15.0 ± 100.4 15.2 ± 57.1 11.8 ± 94.0 20.9 ± 223.1
Data presented as: *Geometric mean ± coefficient of variation; **Median (range); †Mean ± SD; ‡Values for single doses (cohorts 1 and 2) or loading doses
(cohorts 3 to 5); §Values based on maintenance doses unless stated otherwise. Note: The multiple dosing profile was not followed for sufficient time to enable
the calculation of t1/2, CL and Vss for cohorts 3 to 5. AUC0-12, area under the serum concentration-time curve from 0 to 12 hours; Cinf, maximum (end of infusion)
serum concentration; CL, total apparent drug clearance; t1/2, terminal half-life; tmax, time to reach Cinf; Vss, apparent volume of distribution at steady state
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Figure 2 TNF-a serum concentrations following (A) single 250 U/kg dose of AZD9773; (B) multiple AZD9773 doses.
 
vs placebo 
% reduction 
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Cohort 5 69.7 (45.2, 83.2) 
P=0.016 P=0.007 
P<0.001 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
Placebo Cohort 3 Cohort 4 Cohort 5 
TN
F-
α 
AU
C
 G
LS
 m
ea
n 
AUC, area under the concentration–time curve; CI, confidence interval; GLS, geometric least squares  
Figure 3 Exploratory analysis of TNF-a AUC over treatment: multiple AZD9773 dose cohorts vs placebo.
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constipation (all n = 13, 18.6%; Table 5). The majority of
TEAEs were mild or moderate in intensity and were not
considered by the investigators to be related to study
drug. Investigator-assessed drug-related TEAEs occurred
in 0, 2 (22.2%), 2 (16.7%), 3 (30.0%) and 2 (25.0%)
patients in AZD9773 cohorts 1 to 5, respectively, and in
10 patients (43.5%) who received placebo. In total, four
patients discontinued treatment due to TEAEs (one
AZD9773 patient each with cardiac arrest, sepsis and
cerebral infarction, and atrial fibrillation in a placebo-
treated patient). There was no overall difference in the
type or severity of TEAEs or serious AEs between treat-
ment cohorts (Tables 5 and 6).
Hypoglycemia, generalized edema and hypernatremia
occurred more frequently in some AZD9773 cohorts
compared with other AZD9773 cohorts and placebo
(Table 5).
Treatment-emergent infections
Nineteen of 47 patients (40.4%) who received AZD9773
experienced 31 treatment-emergent infections, while 10/
23 (43.5%) who received placebo experienced 13 treat-
ment-emergent infections. Of these 44 events, 10 had a
fatal outcome (7 and 3 in the AZD9773 and placebo
cohorts, respectively), 16 resolved (10 and 6 in the
AZD9773 and placebo cohorts, respectively) and 18
were ongoing at the end of the study period (14 and 4
in the AZD9773 and placebo cohorts, respectively).
Laboratory data
Assessment of laboratory data showed changes within
individual patients for a number of parameters. How-
ever, there was no clear evidence that the pattern of
laboratory data differed between the AZD9773 cohorts
and placebo patients and there was a general trend
towards an improvement over time. Furthermore, there
was no apparent effect of increased exposure to
AZD9773 on laboratory parameters.
Total human anti-sheep antibody (HASA) and HASA
IgG levels were undetectable at baseline. Following
AZD9773 treatment, total HASA levels were positive in
one patient in cohort 3 and five patients in cohort 4,
and undetected in the remainder of the patients. HASA
IgG was positive following AZD9773 treatment in two
patients in cohort 3, three patients in cohort 4 and two
patients in cohort 5.
Electrocardiogram assessment
Small fluctuations in ECG evaluations around baseline
values were observed during treatment for all para-
meters within all groups, although there were no nota-
ble differences or obvious trends. AZD9773 had no
discernible effect on QTc interval.
Table 5 Most common treatment-emergent adverse events, irrespective of relationship to study drug (safety
population)*
AZD9773 cohort
1
(50 U/kg)
(n = 8)
AZD9773 cohort
2
(250 U/kg)
(n = 9)
AZD9773 cohort 3
(250/50 U/kg) (n =
12)
AZD9773 cohort 4
(500/100 U/kg) (n =
10)
AZD9773 cohort
5
(750/250 U/kg)
(n = 8)
Placebo
(n = 23)
Patients with any
TEAE
8 (100.0) 9 (100.0) 12 (100.0) 8 (80.0) 7 (87.5) 23
(100.0)
Anemia 1 (12.5) 3 (33.3) 2 (16.7) 1 (10.0) 2 (25.0) 4 (17.4)
Agitation 2 (25.0) 2 (22.2) 1 (8.3) 3 (30.0) 1 (12.5) 4 (17.4)
Constipation 2 (25.0) 2 (22.2) 2 (16.7) 1 (10.0) 0 6 (26.1)
Generalized edema 0 1 (11.1) 3 (25.0) 2 (20.0) 3 (37.5) 3 (13.0)
Hypoglycemia 1 (12.5) 1 (11.1) 1 (8.3) 4 (40.0) 3 (37.5) 2 (8.7)
Hypokalemia 2 (25.0) 1 (11.1) 0 2 (20.0) 0 7 (30.4)
Hypernatremia 1 (12.5) 1 (11.1) 0 3 (30.0) 2 (25.0) 2 (8.7)
Hypophosphatemia 2 (25.0) 1 (11.1) 0 2 (20.0) 1 (12.5) 2 (8.7)
Diarrhea 2 (25.0) 0 0 1 (10.0) 1 (12.5) 4 (17.4)
Edema peripheral 2 (25.0) 0 0 0 1 (12.5) 4 (17.4)
Insomnia 1 (12.5) 2 (22.2) 0 1 (10.0) 0 2 (8.7)
Sepsis 1 (12.5) 0 3 (25.0) 0 0 1 (4.3)
Wheezing 1 (12.5) 2 (22.2) 0 1 (10.0) 0 1 (4.3)
Bradycardia 0 0 0 2 (20.0) 0 3 (13.0)
Feeding disorder 1 (12.5) 2 (22.2) 0 0 0 1 (4.3)
Decubitus ulcer 1 (12.5) 0 0 2 (20.0) 1 (12.5) 0
Hypertension 0 1 (11.1) 0 2 (20.0) 1 (12.5) 0
Scleral hemorrhage 2 (25.0) 0 0 0 0 0
*Data arranged in order of overall frequency (≥ 20% in any cohort)
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Mortality
The overall 28-day mortality was 27.7% (n = 13/47)
across the AZD9773 cohorts and 26.1% (n = 6/23) in
placebo patients (Table 7). The most common causes of
death were sepsis and septic shock (n = 4 for each), and
pneumonia and respiratory failure (n = 2 for each). No
deaths were considered by the investigator to be related
to study drug.
Sepsis care
The median number of shock-free days on Day 7 was
4.0 in the placebo group and ranged from 2.0 to 4.5 in
Table 6 Serious treatment-emergent adverse events, irrespective of relationship to study drug (safety population)*
AZD9773 cohort
1
(50 U/kg)
(n = 8)
AZD9773 cohort
2
(250 U/kg)
(n = 9)
AZD9773 cohort 3
(250/50 U/kg) (n =
12)
AZD9773 cohort 4
(500/100 U/kg) (n =
10)
AZD9773 cohort
5
(750/250 U/kg)
(n = 8)
Placebo
(n =
23)
Patients with any serious
TEAE
3 (37.5) 6 (66.7) 7 (58.3) 3 (30.0) 4 (50.0) 13
(56.5)
Sepsis 1 (12.5) 0 3 (25.0) 0 0 1 (4.3)
Pneumonia 1 (12.5) 1 (11.1) 0 0 0 2 (8.7)
Septic shock 0 1 (11.1) 0 0 1 (12.5) 2 (8.7)
Respiratory failure 0 0 0 2 (20.0) 0 2 (8.7)
Cardiac arrest 1 (12.5) 1 (11.1) 0 0 0 1 (4.3)
Pulmonary embolism 0 1 (11.1) 0 0 1 (12.5) 1 (4.3)
Deep vein thrombosis 0 0 1 (8.3) 1 (10.0) 0 1 (4.3)
Hemorrhagic shock 0 0 1 (8.3) 0 0 1 (4.3)
Empyema 0 0 1 (8.3) 0 0 0
Endocarditis 0 1 (11.1) 0 0 0 0
Cellulitis 0 0 0 0 0 1 (4.3)
Acute myocardial infarction 0 0 0 1 (10.0) 0 0
Cardiac failure 0 0 1 (8.3) 0 0 0
Supraventricular tachycardia 0 0 0 1 (10.0) 0 0
Atrial fibrillation 0 0 0 0 0 1 (4.3)
Pneumonia aspiration 0 0 0 1 (10.0) 0 0
Hypoxia 0 0 0 0 0 1 (4.3)
Shock 0 0 1 (8.3) 0 0 0
Peripheral ischemia 0 0 0 0 0 1 (4.3)
Enterocutaneous fistula 0 0 0 0 1 (12.5) 0
Intestinal ischemia 0 0 0 0 1 (12.5) 0
Intestinal perforation 0 0 0 0 0 1 (4.3)
Medical device complication 0 1 (11.1) 0 0 0 0
Acidosis 0 1 (11.1) 0 0 0 0
Malignant lung neoplasm 0 1 (11.1) 0 0 0 0
Cerebral infarction 0 0 1 (8.3) 0 0 0
Intracranial hemorrhage 0 0 0 0 0 1 (4.3)
Toxic epidermal necrolysis 1 (12.5) 0 0 0 0 0
Muscle hemorrhage 0 0 0 0 0 1 (4.3)
*Data arranged in order of overall frequency
Table 7 28-day mortality (safety population)
AZD9773 cohort
1
(50 U/kg)
(n = 8)
AZD9773 cohort
2
(250 U/kg)
(n = 9)
AZD9773 cohort 3
(250/50 U/kg) (n =
12)
AZD9773 cohort 4
(500/100 U/kg) (n =
10)
AZD9773 cohort
5
(750/250 U/kg)
(n = 8)
Placebo (n =
23)
Alive, n (%) 6 (75.0) 5 (55.6) 7 (58.3) 9 (90.0) 7 (87.5) 16 (69.6)
Dead, n (%) 2 (25.0) 4 (44.4) 5 (41.7) 1 (10.0) 1 (12.5) 6 (26.1)
Lost to follow-up, n
(%)
0 0 0 0 0 1 (4.3)
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the AZD9773 cohorts; equivalent values on Day 14 were
11.0 in the placebo group and 7.5 to 11.5 in the
AZD9773 cohorts (see Additional file 4). The median
number of ventilator-free days was 19.0 in the placebo
group and ranged from 8.0 to 22.5 in the AZD9773
cohorts (see Additional file 4).
Concomitant medication
Concomitant drotrecogin alfa was received by 16
patients (22.9%) during the study, including 10/47
(21.3%) AZD9773 patients and 6/23 (26.1%) placebo
patients. For patients receiving drotrecogin alfa, the
median APACHE II score was 31 (range 13 to 41) in
the AZD9773 cohorts and 27 (range 21 to 37) in the
placebo group.
Forty-two patients (60%) received concomitant corti-
costeroids during treatment, predominantly, but not
exclusively, early in the septic period; this comprised 28/
47 (59.6%) AZD9773 patients and 14/23 (60.9%) placebo
patients. There were seven deaths due to infection in
AZD9773-treated patients and all received concomitant
corticosteroids. There were three deaths due to infection
in the placebo-treated patients; one received concomi-
tant corticosteroids.
Sequential Organ Failure Assessment scores
In general, median SOFA scores decreased during the
treatment period (see Additional file 5). The total organ
failure resolution rate was 57.4% (27/47) in the
AZD9773 cohorts and 60.9% (14/23) in the placebo
group.
Discussion
This double-blind, randomized Phase IIa study demon-
strated that at the dose regimens and infusion rates stu-
died, AZD9773 was well tolerated with an acceptable
safety profile. Although earlier studies of TNF-a sup-
pression have been associated with only modest clinical
benefit, AZD9773 has a number of potential advantages
over previously evaluated agents [9]. As a polyclonal Fab
fragment, it binds to multiple domains of TNF-a and is
likely to exhibit improved tissue penetration [9-12]. A
previous Phase II efficacy study with CytoFab demon-
strated an increased number of ventilator- and ICU-free
days, with a trend towards improved mortality, com-
pared with placebo in patients with severe sepsis [13].
Informal comparison between the safety and PK/PD
data reported here and previously reported CytoFab
data [13] suggest that changes to the manufacturing
process have not adversely impacted the safety or toler-
ability profile of the drug.
Most patients in both the AZD9773 cohorts and pla-
cebo group completed the treatment period (63/70;
90.0%). In general, the AZD9773 cohorts and placebo
patients were comparable for safety and tolerability, and
there was no apparent increase in the incidence or
severity of AEs or changes in laboratory parameters
with increasing exposure to AZD9773. Although pro-
gression of sepsis and its treatment confounded detailed
analysis, there were no apparent patterns in TEAE or
laboratory data, or consistent relationship to administra-
tion of AZD9773, to support an association between
AZD9773 treatment and a specific TEAE. The incidence
of TEAEs considered at the time of the event as being
related to study drug by the reporting investigator was
lower in patients who received AZD9773 than in those
who received placebo. The 28-day mortality rate was
similar between placebo and AZD9773-treated patients
and, although the number of patients in each cohort
was small, was in keeping with expected mortality rates
in this patient population.
Across the doses studied, AZD9773 exposure increased
in an approximately dose-proportional manner. Large
inter-patient variability in exposure was observed,
although a population PK/PD analysis demonstrated a
potential relationship with creatinine clearance (CrCL)
[23]. Patients with lower CrCL had higher AZD9773
exposure; however, the increase was not expected to
exceed a 10-fold range within this patient population.
Patients with renal dysfunction were not excluded from
this study and, although low CrCL rates were observed,
there was no increase in adverse events in these patients
due to exposure. There was no additional impact on
AZD9773 exposure in patients on dialysis compared with
other study patients. Although both total and specific
AZD9773 Fabs were detected in dialysate samples, there
was no evidence of reduced exposure to AZD9773 in
serum from patients with renal dysfunction.
Approximately 15% of AZD9773 was excreted in
urine. Comparison of renal clearance to total serum
clearance suggests that between 25% and 33% of drug
clearance is renal. This indicates that renal elimination
plays an important role in the clearance of AZD9773,
although most is likely to be cleared through the reticu-
loendothelial system. Current studies do not preclude
administration of AZD9773 to patients with renal
impairment.
The terminal t1/2 of AZD9773 was approximately 20
hours and was multi-phasic, with most inhibitory activ-
ity occurring within the first phase, resulting in an
immediate suppression of TNF-a levels. In AZD9773
cohorts 3 to 5, TNF-a detection declined significantly
within two hours post-infusion, and the apparent TNF-
a suppression was maintained throughout treatment
(Figure 2B). While it has not been possible to formally
demonstrate a loss of TNF-a bioactivity following
AZD9773 dosing (due to assay feasibility issues), it is
highly likely that TNF-a bioactivity is correspondingly
diminished. AZD9773 is a polyclonal TNF-a-neutraliz-
ing agent, and characterization of the AZD9773:TNF-a
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interaction reveals that multiple AZD9773 Fabs bind per
TNF-a monomer [24]. Indeed, AZD9773 competes with
various commercially available TNF-a detection Ab sys-
tems and novel phage-Ab anti-TNF binding antibody
fragments (data not shown), making detection of TNF-a
in the presence of AZD9773 problematic. However, the
typical molar ratios of AZD9773:TNF-a present in the
serum of patients in this study make it highly likely that
TNF-a bioactivity will be completely neutralized.
The relatively short t1/2 of AZD9773 resulted in an
immediate increase in TNF-a levels following cessation
of dosing, with the rapid 80 to 90% decline in serum con-
centration observed within the first 12 hours facilitating
the subsequent normalization of TNF-a levels. Although
there was no apparent impact of AZD9773 on IL-6 and
procalcitonin levels compared with placebo, these para-
meters will continue to be assessed in larger studies that
are specifically designed to assess efficacy outcomes.
A previously reported population PK/PD analysis
demonstrated a proportional relationship between TNF-
a suppression and AZD9773 exposure [23]. The PK
profiles and the concentration-effect relationships with
TNF-a were comparable between AZD9773 and Cyto-
Fab [13]. The population PK/PD model was used to
simulate potential doses for use in future clinical stu-
dies, from which a 750 U/kg loading dose followed by
250 U/kg maintenance doses was deemed unlikely to
provide any additional overall improvement in TNF-a
suppression compared with 500 U/kg loading and 100
U/kg maintenance doses, or 250 U/kg loading and 50
U/kg maintenance doses. These latter two doses are
therefore being employed in the ongoing Phase IIb stu-
dies (ClinicalTrials.gov identifiers: NCT01145560 and
NCT01144624).
As an exogenous protein, AZD9773 might be expected
to generate an immunological reaction in some patients.
However, this study had limited ability to fully charac-
terize any potential reaction for a variety of reasons: the
small number of patients in each cohort; concomitant
medications received; the disease under study; and the
relatively short duration of follow-up.
The incidence of recipient antibody formation
reported with the use of biological therapies varies
widely in the literature, ranging from 0 to 100% depend-
ing on the type of product and patient population [25].
Here, HASAs were not expected to reduce AZD9773
efficacy, given the time required for their formation rela-
tive to the short duration of treatment. A small number
of patients developed HASAs in this study (6/47; 12.8%),
the incidence of which was not dose related and was
lower than that reported with CytoFab (11/27; 40.7%)
[13]. Data from similar products, such as crotalidae
polyvalent immune Fab (CroFab®, BTG International
Inc., London, UK) [26] and digoxin immune Fab (Digi-
bind®, BTG International Inc., London, UK) [27], also
suggest that HASAs are unlikely to pose a significant
safety risk, given the short duration of treatment pro-
posed for AZD9773.
An important limitation in this study was the small
patient sample size, as the study population was not suf-
ficiently large to detect clinical benefit.
Conclusions
In conclusion, the data support further assessment of
this ovine-derived, anti-TNF-a antibody fragment in
patients with severe sepsis. Larger, randomized, global
Phase IIb clinical trials are ongoing to further character-
ize the safety and efficacy of AZD9773 in this patient
population.
Key messages
■ TNF-a, an early mediator in the systemic inflamma-
tory response to infection, is a therapeutic target in sep-
sis. AZD9773 is an ovine-derived, polyclonal, anti-
human TNF-a Fab preparation in development for the
treatment of patients with severe sepsis and septic
shock.
■ This double-blind, randomized Phase IIa study
showed that most adverse events during AZD9773 treat-
ment were of mild-to-moderate intensity and considered
by the investigator as unrelated to study treatment.
■ AZD9773 pharmacokinetic data demonstrated an
approximately proportional increase in concentration
with increasing dose and a terminal half-life of 20 hours.
■ Serum TNF-a concentrations decreased to near-
undetectable levels within two hours of commencing
AZD9773 infusion.
■ The safety, pharmacokinetic and pharmacodynamic
data support the continued evaluation of AZD9773 in
larger Phase IIb/III studies.
Additional material
Additional file 1: Study definitions. A list of definitions for the
inclusion criteria of the study.
Additional file 2: Table S1. Organ dysfunction definitions. Table listing
the definitions of organ dysfunction used in the study, to go with
Additional file 1.
Additional file 3: Figure S1. Timing of severe sepsis inclusion criteria.
Diagram showing the timescales for the inclusion criteria, to go with
Additional file 1.
Additional file 4: Shock- and ventilator-free days (safety
population). Table showing the number of shock- and ventilator-free
days in the safety population.
Additional file 5: Median (range) SOFA scores over time (safety
population). Table showing the SOFA scores in the safety population
over time.
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